GSK plc (GSK) Form 6-K — Oct 26, 2026
GSK's licensed partner Hansoh Pharmaceutical reported positive phase III results from the ARTEMIS-011 trial in China, where Ris-Rez reduced the risk of disease progression or death by 67% versus chemotherapy in patients with relapsed osteosarcoma after at least two prior lines of therapy. Patients on Ris-Rez remained progression-free for a median of 5.5 months versus 1.4 months with chemotherapy (HR 0.33; p<0.0001), and results were presented at a Presidential Symposium at the ESMO Congress 2026.
Key figures
- Hazard ratio
- 0.33
- Grade3 plus trae chemo
- 83%
- Median followup months
- 7.1
- Risk reduction percent
- 67
- Median pfs months chemo
- 1.4
- Grade3 plus trae ris rez
- 93%
- Median pfs months ris rez
- 5.5
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.